Clinical Trials on Upper Respiratory Tract Infection (URTI) in Japan

Total 1155 results

Pfizer

Completed

A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Upper Respiratory Tract Infection

Japan
Bayer

Completed

Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease

Anti-Infective Agents

Japan
Taiko Pharmaceutical Co., Ltd.

Unknown

Test of a Preventive Effect of a Deodorant Device Against Respiratory Infections (Cleverin)

Respiratory Infection

Japan
Gifu Prefecture Medical Association
Sanofi Pasteur S.A.

Completed

Seroepidemiological Study of Pertussis and Other Infectious Diseases

Pertussis Infection

Japan
Janssen R&D Ireland

Completed

A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections

Respiratory Syncytial Virus

Japan
University of Shizuoka

Unknown

Gargling With Green Tea for Prophylaxis of Influenza Infection in Teenagers

Influenza Infection

Japan
University of Shizuoka
Hamamatsu University; Seirei Hamamatsu General Hospital

Completed

Catechin Containing Mask for the Prevention of Influenza Infection

Influenza Infection

Japan
Masahiro Morikawa
White Cross Nursing Home

Completed

Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection

Influenza Infection

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

SARS-CoV-2 Infection( COVID-19 )

Japan
Pfizer

Completed

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

SARS-CoV-2 Infection

Japan
University of Shizuoka
White Cross Nursing Home; Seirei Hamamatsu General Hospital; Shizuoka General...

Completed

Catechin Gargling for Influenza Infection

Influenza Infection

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)

COVID-19 Lower Respiratory Infection

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2

Japan
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
Janssen Research & Development, LLC

Completed

A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infections

Japan
Meiji Seika Pharma Co., Ltd.

Recruiting

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (Integral-2)

Acute Pyelonephritis | Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection | Ventilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia

Japan
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
Takeda

Completed

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Japan
GlaxoSmithKline

Completed

Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children

Influenza

Japan
GlaxoSmithKline

Completed

Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males

Influenza, Human

Japan
AstraZeneca

Terminated

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
UMN Pharma Inc.

Completed

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

A Study to Evaluate Intramuscular ASP7374

Influenza | Vaccine

Japan
GlaxoSmithKline

Completed

Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older

Influenza

Japan
Nitto Denko Corporation

Completed

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Influenza

Japan
Sanofi

Completed

Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia

Pneumonia

Japan
Pfizer

Completed

Drug Use Investigation of COMIRNATY Intramuscular Injection

COVID-19

Japan
AstraZeneca

Completed

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan (Evusheld DBR)

COVID-19

Japan
Pfizer

Completed

Special Investigation of COMIRNATY in the Population With Underlying Diseases

COVID-19

Japan
AnGes, Inc.

Completed

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

COVID-19

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

COVID-19

Japan
AbbVie (prior sponsor, Abbott)

Completed

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Respiratory Syncytial Virus Infection

Japan
Sanofi Pasteur, a Sanofi Company
Sanofi K.K.

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Influenza

Japan
Genova Inc.
Tokyo Shinagawa Hospital

Recruiting

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

Covid19

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Influenza

Japan
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Bayer

Completed

Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance

Infection

Japan
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

Influenza

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
Bayer

Completed

Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution

Infection

Japan
UMN Pharma Inc.

Completed

Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza | Vaccine

Japan
Pfizer

Active, not recruiting

Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

COVID-19 | SARS-CoV-2

Japan
ModernaTX, Inc.

Completed

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Coronavirus Disease (COVID-19)

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Yubari Kibounomori
Health Research Foundation

Completed

Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist

Pneumonia

Japan
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
ModernaTX, Inc.

Completed

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

SARS-CoV-2

Japan
ModernaTX, Inc.

Completed

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

SARS-CoV-2

Japan
Takeda

Withdrawn

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Coronavirus Disease (COVID-19)

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Covid19

Japan

3

Subscribe